What is The Problem with Yaz?
Women who use Yasmin or Yaz may face an increased risk of blood clots, heart attack, deep vein thrombosis (DVTs), stroke, kidney or gallbladder problems and other side effects due to the unique hormone combination in these medications. The manufacturers have failed to warn of the increased risk.
Yasmin, which was approved by the Food and Drug Administration in 2001, and Yaz, approved in 2006, contain the hormone drospirenone (DRSP). DSRP is useful as a contraceptive and can also help to treat acne and to prevent weight gain and bloating during menstruation.
However, the DRSP in Yaz and Yasmin can also lead to high levels of potassium in the blood, a condition known as hyperkalemia. This increased potassium can cause a number of serious and potentially deadly side effects for women using Yaz or Yasmin, including blood clots, heart attack, stroke, gallbladder problems, kidney failure and liver failure.
According to two studies published in the British Medical Journal (BMJ), women taking Yaz, Yasmin or Ocella (the generic version of Yasmin) are twice as likely to suffer blood clots compared to other popular birth control pills. Since 2004, the FDA has received reports of a significant number of deaths among women using Yaz or Yasmin.
In 2008, the FDA forced Bayer Pharmaceuticals to air a $20 million ad campaign stating that the company improperly marketed Yaz in commercials as a treatment for acne and PMS symptoms—which it was not approved to treat—while downplaying the drug’s side effects risk.